Hepatitis B antiviral agents
US10428070B2 · kind B2 · utility
23Cited by
24References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 5, 2018 |
| Grant date | Oct 1, 2019 |
| Priority date | — |
| Expiry date | Dec 5, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.